[HTML][HTML] 90Y-edotreotide for metastatic carcinoid refractory to octreotide

…, H Bouterfa, Y Li, KA Kacena, N LaFrance… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea
and flushing, can be debilitating and occasionally life-threatening. Although symptom relief …

Local cerebral glucose abnormalities in mild closed head injured patients with cognitive impairments

MS Humayun, SK Presty, ND Lafrance… - Nuclear Medicine …, 1989 - journals.lww.com
Mild-moderate closed head injury (CHI) can be followed by neuropsychological impairments
in recent memory and attention, despite the absence of discernible structural abnormalities …

Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment

…, JR Parker, K Bensel, ND LaFRANCE - Investigative …, 1999 - journals.lww.com
Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of
gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999; 34: 443–448. …

Creatinine measurements often yield false estimates of progression in chronic renal failure

M Walser, HH Drew, ND LaFrance - Kidney international, 1988 - Elsevier
LAFRANCELAFRANCE NB, DREW H, WALSER M: Radioisotopic measurement of
glomerular … WALSER M, LAFRANCE ND, WARD L, VANDUYN MA: Progression of chronic renal …

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy …

…, H Shimada, J Barrett, N LaFrance… - Journal of Nuclear …, 2012 - Soc Nuclear Med
131 I-metaiodobenzylguanidine (MIBG) is specifically taken up in neuroblastoma, with a
response rate of 20%–37% in relapsed disease. Nonradioactive carrier MIBG molecules inhibit …

Radiation dosimetry, pharmacokinetics, and safety of ultratrace™ iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic …

…, JA Barrett, M de la Guardia, N LaFrance… - Cancer biotherapy …, 2009 - liebertpub.com
This is a first-in-man phase 1 study of Ultratrace™ Iobenguane I-131 (Ultratrace 131 I-MIBG;
Molecular Insight Pharmaceuticals, Inc., Cambridge, MA). High-specific-activity Ultratrace …

Bone mineral density of eating disorder subgroups

…, PJ Woodward, N LaFrance - International Journal of …, 1995 - Wiley Online Library
Objective: We tested nine hypotheses among eating disorder subgroups and a control group
on spinal bone density and investigated the relationship of their spinal bone density with a …

Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients

BL Laube, JM Links, ND LaFrance, HN Wagner Jr… - Chest, 1989 - Elsevier
We characterized the bronchopulmonary distribution of a 0.9 percent saline aerosol (1.12
µM) labelled with 99m Tc sulfur colloid in nine normal subjects and five patients with CF. …

Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter …

…, T Armor, KA Kacena, ND LaFrance… - Journal of the American …, 2010 - jacc.org
Objectives : The aim of this study was to assess the performance of β-methyl-p-[ 123 I]-iodophenyl-pentadecanoic
acid (BMIPP) single-photon emission computed tomography (SPECT) …

Radioisotopic measurement of glomerular filtration rate in severe chronic renal failure.

ND LaFrance, HH Drew, M Walser - Journal of nuclear medicine …, 1988 - europepmc.org
In order to determine the best method for routine measurement of glomerular filtration rate (GFR)
in severe renal failure, we compared simultaneously the urinary clearances of [99mTc] …